CCL5 and gastric cancer: Most importantly, either suppressing DNMT enzyme activity, or treatment with demethylation agent, or interfering with CCL5/CCR5/STAT3 pathway led to decreased in vivo tumor growth, suggesting several possible routes of epigenetic inhibition of gastric cancer development [228].